Astellas Pharma (4503.T)

Executive Summary

Astellas Pharma is a Japan-based global pharmaceutical company focused on oncology, urology, nephrology, and immunology. The company has a robust pipeline of over 1,180 projects, from discovery to late-stage trials, and markets products in over 70 countries. Key approved drugs include mirabegron (Myrbetriq) for overactive bladder and enzalutamide (XTANDI) for prostate cancer, which continue to drive revenue. However, patent expirations and generic competition pose headwinds. Astellas is investing in next-generation therapies, including antibody-drug conjugates and gene therapies, to sustain growth. The company's strategic focus on transformative medicines positions it well for long-term value creation, though near-term earnings may be pressured by R&D costs and market exclusivity losses. Overall, Astellas offers a balanced risk-reward profile with a diversified portfolio and several late-stage pipeline assets that could catalyze upside.

Upcoming Catalysts (preview)

• Q3 2026FDA decision on zolbetuximab (Vyloy) for advanced gastric cancer70% success
• Q4 2026Phase 3 readout for enzalutamide + radium-223 in metastatic castration-resistant prostate cancer60% success
• Q2 2026Regulatory filing for fezolinetant in Europe for vasomotor symptoms85% success